Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL

Summary

The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia (CLL), to facilitate access for the National Institute of Health and Medical Research (INSERM) to patients with double-refractory CLL. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent. These samples will first be sent to the Filothèque for temporary storage, and will then be transferred to CRCI²NA (Nantes - Angers Cancer and Immunology Research Center) for analysis with the aim of studying the mechanisms of resistance and response to BTK degraders (BTKd).

Eligibility

Inclusion Criteria:

* Patient with confirmed double refractory CLL to both BTKi and BCL-2i, defined as:

  * Any patient who has received both a BTKi and a BCL-2i, regardless of treatment regimen, and has shown clinical progression either during treatment with both BTKi and BCL-2i, or within 36 months after stopping BCL-2i.
  * Any patient identified with known biological resistance mutations to BTKi or BCL-2i, regardless of clinical progression.
* Patient who has provided informed consent to participate in the study.
* Patient covered by a social security health insurance plan

Exclusion Criteria:

* Minor patients.
* Adults under guardianship.
* Protected persons.

Conditions3

Browse More Trials